Cantor Fitzgerald Reiterates Overweight on Vaxcyte, Announces $120 Price Target
Cantor Fitzgerald analyst Carter Gould reiterates Vaxcyte (NASDAQ:PCVX) with a Overweight and announces $120 price target.
Stocks · News reference
Reported Earlier, Vaxcyte Prices 7,412,500 Common Shares At $64.00 Each, 400,000 Pre-Funded Warrants And $500M 1.50% Convertible Notes Due 2032 In Concurrent Offerings
Reference Details
Connected Markets
Poisar stores the source's headline, summary and market tags for reference. Reporting and full article text remain with the original publisher.
- Source
- benzinga
- Observed
- Checked
- Cadence
- Captured once, then retained as an archive reference
- Status
- fresh
Keep reading
Related Headlines
Stephen King Slams Trump’s New Press Secretary as Past Vaccine Conspiracy Theories, Third-Term Posts Spark Fresh Controversy: 'She Appears to Have Tried to…'
Stephen King slammed Trump’s incoming press secretary over her vaccine conspiracy theories and controversial posts.
8-K filing — Vaxcyte, Inc. (PCVX)
Filed: 2026-10-09 AccNo: 0001193125-26-419174 Size: 2 MB Item 1.01: Entry into a Material Definitive Agreement Item 2.03: Creation of a Direct Financial Obligation or an Obligation under an Off-Balance Sheet Arrangement of a Registrant Item 8.01: Other Events Item 9.01: Financial Statements and Exhibits
A New War on Cancer? NIH's Vaccine Initiative Sparks Biotech Stock Rally
A new NIH-backed initiative to speed up personalized cancer vaccine development sent stocks like MRNA, BNTX, and NVAX surging Friday.